Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
5(56%)
Results Posted
33%(1 trials)

Phase Distribution

Ph phase_1
1
11%
Ph phase_2
4
44%
Ph phase_3
4
44%

Phase Distribution

1

Early Stage

4

Mid Stage

4

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
1(11.1%)
Phase 2Efficacy & side effects
4(44.4%)
Phase 3Large-scale testing
4(44.4%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

5

trials recruiting

Total Trials

9

all time

Status Distribution
Active(6)
Completed(3)

Detailed Status

Recruiting4
Completed3
Active, not recruiting1
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
5
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (11.1%)
Phase 24 (44.4%)
Phase 34 (44.4%)

Trials by Status

recruiting444%
completed333%
active_not_recruiting111%
enrolling_by_invitation111%

Recent Activity

5 active trials
Showing 5 of 9
recruitingphase_2

A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old

NCT07722546
recruitingphase_3

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)

NCT06962800
enrolling_by_invitationphase_3

A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE)

NCT07444489
recruitingphase_3

A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

NCT06935357
recruitingphase_2

A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation

NCT07219043
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT07722546Phase 2

A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old

Recruiting
NCT06962800Phase 3

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)

Recruiting
NCT07444489Phase 3

A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE)

Enrolling By Invitation
NCT06935357Phase 3

A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

Recruiting
NCT07219043Phase 2

A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation

Recruiting
NCT06064929Phase 1

A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old

Completed
NCT06685757Phase 3

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)

Active Not Recruiting
NCT05065970Phase 2

Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy

Completed
NCT05021484Phase 2

Felzartamab in Late Antibody-Mediated Rejection

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9